Miltefosine Alternatives Compared
| Miltefosine | Allopurinol | Amphotericin b |
|
|---|
| Miltefosine | Allopurinol | Amphotericin b |
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Leishmaniasis. Miltefosine may also be used for purposes not listed in this medication guide. |
Prescription only
Allopurinol is used in the treatment of high uric acid levels associated with gout, kidney stones, and cancer treatment, it should not be used for asymptomatic high uric acid levels. If a rash occurs... View more |
Prescription only
Prescribed for Blastomycosis, Aspergillosis - Aspergilloma, Aspergillosis - Invasive, Candida Urinary Tract Infection, Candidemia, Coccidioidomycosis, Coccidioidomycosis - Meningitis, Cryptococcal... View more |
Related suggestions Leishmaniasis
|
|||||||||||||||
| More about Miltefosine | More about Allopurinol | More about Amphotericin b | ||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||
|
Be the first to share your experience with this drug. |
Allopurinol has an average rating of 7.5 out of 10 from a total of 88 ratings on Drugs.com. 63% of reviewers reported a positive effect, while 19% reported a negative effect. |
Amphotericin b has an average rating of 1.0 out of 10 from a total of 1 ratings on Drugs.com. 0% of reviewers reported a positive effect, while 100% reported a negative effect. |
||||||||||||||||
| Drug Class | ||||||||||||||||||
| Side Effects | ||||||||||||||||||
| Generic Availability | ||||||||||||||||||
|
N/A |
Lower cost generic |
Lower cost generic |
||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||
|
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Allopurinol prices |
View all Amphotericin b prices |
||||||||||||||||
| Dosage Forms Available | ||||||||||||||||||
|
N/A |
|
|
||||||||||||||||
| Brand Names | ||||||||||||||||||
| Impavido | Aloprim, Zyloprim |
N/A |
||||||||||||||||
| Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||||||||||
|
736.8 hours |
27 hours |
360 hours |
||||||||||||||||
| CSA Schedule ** View glossary of terms | ||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
| Pregnancy Category | ||||||||||||||||||
|
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
||||||||||||||||
| Drug Interactions | ||||||||||||||||||
|
A total of 6 drugs are known to interact with Miltefosine:
|
A total of 431 drugs are known to interact with Allopurinol:
|
A total of 174 drugs are known to interact with Amphotericin b:
|
||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||
| Disease Interactions | ||||||||||||||||||
| First Approval Date | ||||||||||||||||||
|
March 19, 2014 |
August 19, 1966 |
N/A |
||||||||||||||||
| WADA Class View World Anti-Doping Agency classifications. | ||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||
| More Information | ||||||||||||||||||
| Patient resources | ||||||||||||||||||
| Professional Resources | ||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||
|
||||||||||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.